Form 4: Cognition Therapeutics CEO Reports RSU Vesting, Tax Sales

Cognition Therapeutics CEO Lisa Ricciardi reported the vesting of 800,000 restricted stock units and subsequent sales to cover tax obligations.

Summary

• Lisa Ricciardi, CEO, President, and Director of Cognition Therapeutics Inc. (CGTX), reported changes in her beneficial ownership.
• On February 3, 2026, Ricciardi acquired 800,000 shares of Common Stock through the vesting of restricted stock units (RSUs) at a price of $0.00 per share.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
• On February 3, 2026, 26,036 shares of Common Stock were disposed of at $1.12 per share to cover tax withholding obligations related to the RSU vesting.
• On February 4, 2026, an additional 51,704 shares of Common Stock were disposed of at $1.03 per share, also to cover tax withholding obligations.
• Following these transactions, Ricciardi directly beneficially owns 1,712,526 shares of Common Stock.
• An additional 38,851 shares are indirectly beneficially owned by her spouse.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as the RSU vesting represents a form of compensation and continued alignment of the CEO's interests with the company's performance. The sales are routine for tax purposes and do not indicate a negative sentiment.

Positives

• The vesting of 800,000 restricted stock units (RSUs) for the CEO indicates continued compensation and alignment of management's interests with shareholders.

Negatives

• A total of 77,740 shares were disposed of over two days to cover tax withholding obligations, reducing the CEO's direct beneficial ownership.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to restricted stock unit vesting and subsequent tax withholding sales, are common occurrences for executives. These transactions are typically pre-planned under Rule 10b5-1 and do not necessarily reflect a change in management's outlook on the company's future performance.

Stakeholder Impact

• Shareholders: The vesting of RSUs aligns the CEO's long-term interests with shareholder value. The tax-related sales are routine and have minimal impact on the overall market.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax withholding sales). It does not provide new fundamental information about Cognition Therapeutics Inc.'s operational performance, financial health, or strategic direction. Therefore, based solely on this filing, a seasoned investor would likely maintain their current position, as there is no new data to warrant a change in investment thesis.

Keywords

Cognition Therapeutics, CGTX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, CEO, Lisa Ricciardi